I just this morning read an article in the Guardian about a major study of inflammation and heart disease–a four year study from Brigham and Women’s Hospital of 10,000 heart attack survivors. The results showed a 15% reduction in complications for participants who took the anti-inflammatory drug canakinumab–a breakthrough confirming the theory that inflammation contributes to heart disease.
This is great news in itself, but there’s more: what was unusual about this study is that, knowing the inflammation pathway the drug targeted was also known to be involved in cancer risk, the researchers ensured that patients with risk factors for cancer were evenly distributed among the study groups.
The results are in: for patients taking a low dose of the anti-inflammatory drug, lung cancer rates were reduced 26%. In patients with a medium dose, the rate dropped 39%. Patients with the highest dose showed a 67% drop, and their overall cancer death rate was about half that of the placebo group.
It’s early days, of course. There will be lots more research to come before this translates to new cancer treatments. But how great to be able to see the beginnings of a promising line of research. Go science!